Navigation Links
New Hepatitis C Drug Close to Gaining FDA Approval
Date:4/28/2011

THURSDAY, April 28 (HealthDay News) -- Boceprevir, a new medication from Merck & Co. that changes the way hepatitis C is treated, won unanimous support Wednesday from a panel of experts convened by the U.S. Food and Drug Administration.

The drug is one of two new medications against hepatitis C that are up for agency approval. Many experts believe that, if approved, boceprevir and the second medicine, telaprevir, could revolutionize treatment of hepatitis C-linked disease.

The U.S. Centers for Disease Control and Prevention estimated 17,000 new hepatitis C virus infections in the United States in 2007. Many people with the disease have no symptoms until it has caused liver damage, sometimes so severe that a liver transplant is needed.

Studies found that when used with two older drugs, boceprevir reduced levels of the virus more effectively than the existing treatments. Merck, headquartered in Whitehouse Station, N.J., hopes to sell the medication under the brand name Victrelis, according to Dow Jones.

Telaprevir, a similar drug made by Vertex Pharmaceuticals of Cambridge, Mass., is scheduled for review Thursday by the same panel of non-FDA experts.

Debra Birnkrant, director of FDA's antiviral-drugs division, said that both medications appear to increase the cure rate "to more than 30 percent above what we have today," Dow Jones reported.

The new drugs take treatment of hepatitis C in a new direction. Both boceprevir and telaprevir block protease, an enzyme that helps the virus reproduce. The earlier drugs, pegylated interferon and ribavirin, were meant to boost the immune system's defense against the virus. Together, the combined medications may offer new hope for the thousands of Americans with the contagious liver disease.

Asked if the available data supported use of boceprevir in combination with standard treatment of pegylated interferon and ribavirin, the panel of me
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New screening system for hepatitis C
2. Groundbreaking research to find vaccine for hepatitis C
3. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
4. Vaccination, Prevention Is Beating Back Hepatitis
5. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
6. Hepatitis C treatment less effective in urban minority patients
7. Researchers identify potential new target for treating hepatitis C
8. Donor kidneys from Hepatitis C patients needlessly denied to patients with that infection
9. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
10. New Drug Shows Promise for Curing Hepatitis C
11. Hepatitis C Tied to Higher Kidney Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility ... effort to provide comfort to patients as well as visiting friends and family during ... phone charging stations. , The stations - powered by ChargeItSpot , a Philadelphia-based ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s ... and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate ... collaboration, OncLive’s editorial and marketing groups will help spread the news about the ...
(Date:7/30/2015)... ... , ... Zejax is a New Way of Training Without ... , World renown body weight trainer, Paul Ziachik, announces today that he is ... person’s training capability. , The American College of Sports Medicine states that among ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... country Myanmar did not give him more than six months ... life in a Delhi hospital which successfully conducted a live ... 10-hour liver transplant surgery at the Sir Ganga Ram Hospital, ... ago and is now getting ready to return home. ...
... care of patients of Scotland hospitals causing an imbalance in ... official watchdog to ensure //that the standards of effective dietary ... Audit report 50% of the hospitals have not yet analyzed ... who are in a critical condition and any miscalculation in ...
... their hearts face risks. The devices called stents.Stents are used ... passage of// blood. It is inserted into cardiac arteries by ... with drugs are more liable to suffer from internal blood ... compared to patients who use stents that are not medicated. ...
... research keenly studied the effect of discontinuing HIV drug therapy ... can be positively// devastating, reported the study. New England Journal ... in its Nov 30 issue. If the treatment is discontinued, ... AIDS and also suffer from toxic side effects of the ...
... used drugs that are used in treatment of cancer, ... by a research, published by the Journal of Biology.// ... brain damage. The effects may be long lasting. This ... refers to the side effects that are seen in ...
... consume junk food which is over laden with salt especially ... This has resulted in// a difficulty for them to consume ... are used to high salt intake. ,Disasters like ... which ruin the lives of many and can be corrected ...
Cached Medicine News:Health News:Myanmar National Undergoes Successful Liver Transplantation in Delhi 2Health News:Hospital Food Needs Improvement to Meet the Nutritional Needs of the Patient 2Health News:Using Heart Stents Tends to Form More Clots 2Health News:Interrupted Treatment Dangerous to HIV Management 2
(Date:7/30/2015)... July 30, 2015 ... reports analyzing tumor biomarker tests, imaging, endoscopy ... for the global industry by technology and ... Industry (Tumor Biomarker Tests, Imaging, Endoscopy and ... talking about 9 companies and supported with ...
(Date:7/29/2015)... OSAKA, Japan , ... -- ... confirmed,   including Core ... EPS    ... Underlying revenue +6.1% year-to-year (reported revenue growing +8.5% to 446.3 billion yen) ...
(Date:7/29/2015)... Ill. , July 30, 2015  Astellas ... ACTIVE study evaluating the efficacy and safety of ... CRESEMBA® (isavuconazonium sulfate), under development for adults with ... Results from the study demonstrated that the trial ... in overall treatment response in isavuconazole-treated patients at ...
Breaking Medicine Technology:Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... Dec. 8 Cell Therapeutics, Inc. (CTI),(Nasdaq ... follow-up data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line ... of Hematology (ASH) 50th Annual Meeting by,Morschhauser, ... progression-free,survival (PFS) following Zevalin consolidation therapy for ...
... 7 Millennium: The Takeda Oncology,Company today ... randomized, multi-center,Company-sponsored Phase I/II study of VELCADE, ... previously untreated multiple,myeloma (MM). The preliminary analysis ... of four drugs was generally well tolerated ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6
... includes: Mx3005P instrument and custom filter ... (5) filters. The standard filter set ... (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) ... computer, Mx3005P analysis software, Beacon Designer ...
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... Time Thermal Block and its operation ... as quantification of gene expression, genotyping, ... validation of microarray results. Exicycler is ... two molecules, such as protein-protein and ...
Medicine Products: